関連する実験動画

Updated: May 6, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

プラズマのアテロゲン指数と糖尿病前患者との関連 - 横断的な研究

Ali Gohar¹, Muhammad Husnain Ahmad², Azhar Nazir³

¹Department of Medicine, Lahore General Hospital, Lahore, Pakistan.

Endocrinology, diabetes & metabolism

|February 19, 2026

まとめ

プラズマのアテロゲン指数 (AIP) は,糖尿病前期におけるより悪い代謝健康と関連しています. 高いAIPはリスクの増加と相関しており,早期糖尿病と心血管疾患のスクリーニングに使用することを示唆しています.

科学分野:

エンドクリノロジーエンドクリノロジー
心血管の健康について
メタボリックシンドロームとは

背景:

糖尿病前症候群は世界的な健康問題であり,パキスタンは高い罹患率を持っています.
糖尿病の進行のリスクが高い個人を早期に特定することは極めて重要です.
Atherogenic Index of Plasma (AIP) は,インスリン抵抗性および心血管疾患のリスクの潜在的なマーカーです.

研究の目的:

糖尿病前患者におけるAIPと様々な代謝指標の関係を調査する.
リスクのある個人を特定するためのスクリーニングツールとしてAIPの有用性を評価する.

主な方法:

334人の糖尿病前患者 (18~60歳) を対象とした横断的な研究.
データ収集には,人体測定,断食グルコース,HbA1c,および脂質プロファイルが含まれていました.
統計分析には,ANOVA,Chi-square,および多変数回帰を用いた.

主要な成果:

AIPの上昇は,男性の性別,高齢,BMIの上昇,HDLの低下,トリグリセリドの上昇と関連していた.
断食中のグルコースとインスリンレベルは,AIPが高くなるにつれて増加した.
HDLとトリグリセリドは,AIPの最も強い独立した予測因子として特定されました.

結論:

AIPは,糖尿病前の患者の有害な代謝指標と有意に関連しています.
AIPは,糖尿病と心血管疾患リスクの早期スクリーニングのためのシンプルで費用対効果の高いツールとして潜在性を示しています.
AIPを日常的な評価に組み込むことは,糖尿病および関連する合併症の予防に役立ちます.

キーワード:

プラズマのアテロジェニックインデックス心血管疾患心血管疾患糖尿病糖尿病とは糖尿病前症候群糖尿病前症候群糖尿病前症候群糖尿病前症候群

さらに関連する動画

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome

Published on: September 27, 2024

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

関連する概念動画

Coronary Artery Disease I: Introduction

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated...